Pipeline Analytics Report
Showing all 5 results
-
Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2021
$2,500.00 – $7,500.00Select optionsAnti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.
-
Cluster of Differentiation 47 (CD47) Inhibitors – Pipeline Analytics-2021
$2,500.00 – $7,500.00Select optionsCluster of Differentiation 47 (CD47) Inhibitor’s report covers the CD47 market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, and therapy area. CD47 inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.
-
Gamma Delta T cell Therapy-Pipeline Analytics 2021
$2,500.00 – $7,500.00Select optionsGamma Delta T cell Therapy report covers the Gamma Delta T cell Therapy market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, company and phases, therapy area and indications by phases. Gamma Delta T cell Therapy reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in understanding the developmental pipeline with respect to different types of molecules, line of therapy and route of administration (RoA).
-
Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors – Pipeline Analytics-2021
$2,500.00 – $7,500.00Select optionsSignal Transducer and Activator of Transcription 3 (STAT3) Inhibitor’s report covers the STAT3 market opportunity providing key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, therapy area, indication and phases. STAT3 inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.
-
Signaling Regulatory Protein (SIRP) α Inhibitors – Pipeline Analytics 2021
$2,500.00 – $7,500.00Select optionsSignaling Regulatory Protein (SIRP) α Inhibitor’s report covers the SIRP α market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, and therapy area. SIRP α inhibitors reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as monotherapy and combinations.